A5008246620- CAR-T cell therapy research
- Immune Cell Function and Interaction
- Viral Infectious Diseases and Gene Expression in Insects
- Phagocytosis and Immune Regulation
- Virus-based gene therapy research
- Advanced Biosensing Techniques and Applications
- Immunotherapy and Immune Responses
- Immune cells in cancer
- CRISPR and Genetic Engineering
- Animal Nutrition and Physiology
- Probiotics and Fermented Foods
- T-cell and B-cell Immunology
- Salmonella and Campylobacter epidemiology
- Meat and Animal Product Quality
- Nanoparticle-Based Drug Delivery
- Heme Oxygenase-1 and Carbon Monoxide
- Biosimilars and Bioanalytical Methods
- Hematopoietic Stem Cell Transplantation
- Influenza Virus Research Studies
- Adolescent and Pediatric Healthcare
- Trauma, Hemostasis, Coagulopathy, Resuscitation
- Neuroblastoma Research and Treatments
- Immunodeficiency and Autoimmune Disorders
- Vibrio bacteria research studies
- Analytical Chemistry and Chromatography
Washington University in St. Louis
2017-2024
Maxygen (United States)
2022
Compugen (Israel)
2020
Defence Science and Technology Laboratory
2012-2017
University of Surrey
2016
Animal and Plant Health Agency
2016
Salisbury University
2013
Royal Navy
2012
PerkinElmer (United Kingdom)
1988
Chimeric antigen receptor (CAR) T cell therapy is routinely used to treat patients with refractory hematologic malignancies. However, a significant proportion of experience suboptimal CAR cytotoxicity and persistence that can permit tumor escape disease relapse. Here we show prototype pro-lymphoid growth factor able enhance efficacy. We demonstrate long-acting form recombinant human interleukin-7 (IL-7) fused hybrid Fc (rhIL-7-hyFc) promotes proliferation, cells in xenogeneic mouse models,...
Abstract T-cell malignancies are associated with frequent relapse and high morbidity, which is partly due to the lack of effective or targeted treatment options. To broaden use CAR-T cells in pan malignancies, we developed an allogeneic “universal” CD2-targeting cell (UCART2), CD2 antigen deleted prevent fratricide, receptor removed GvHD. UCART2 demonstrated efficacy against T-ALL CTCL prolonged survival tumor-engrafted NSG mice vivo. evaluate impact on function, generated CD19 (UCART19)...
Acute trauma coagulopathy in seriously injured casualties may be initiated by tissue hypoperfusion. A targeted (or novel hybrid [NH]) resuscitation strategy was developed to overcome poor oxygen delivery associated with prolonged hypotension.Under the Animals (Scientific Procedures) Act 1986, terminally anesthetized large white pigs were divided into four groups (n = 6). Groups 1 and 2 received blast injury 3 4 no (sham). All given a controlled hemorrhage (35% blood volume) an uncompressed...
Abstract Multiple myeloma (MM), a malignancy of mature plasma cells, remains incurable. B-cell maturation antigen (BCMA) is the lead protein target for chimeric receptor (CAR) therapy because its high expression in most MM, with limited other cell types, resulting favorable on-target, off tumor toxicity. The response rate to autologous BCMA CAR-T high; however, it not curative and associated risks cytokine release syndrome (CRS) immune effector cell–associated neurotoxicity syndrome....
Abstract Staphylococcal enterotoxin B (SEB) is a bacterial superantigen that binds the receptors in APC/T cell synapse and causes increased proliferation of T cells cytokine storm syndrome vivo. Exposure to toxin can be lethal cause significant pathology humans. The lack effective therapies for SEB exposure remains an area concern, particularly scenarios acute mass casualties. We hypothesized blockade costimulatory signal by CTLA4-Ig synthetic protein (abatacept) could prevent SEB-dependent...
Antibiotic efficacy is greatly enhanced the earlier it administered following infection with a bacterial pathogen. However, in clinical setting antibiotic treatment usually commences onset of symptoms, which some cases (e.g., biothreat agents) may be too late. In BALB/c murine intranasal model for Francisella tularensis SCHU S4 infection, we demonstrate during time course experiment that proinflammatory cytokines and damage-associated molecular pattern HMGB1 were not significantly elevated...
170 Background: CRC is the 4 th leading cause of global cancer-related deaths, and novel therapeutic strategies for advanced are urgently needed. Adoptive cell therapy (ACT) effective in treating hematological malignancies; however, ACT solid tumors hindered by target antigen identification, restricted migration into tumors, survival tumor microenvironment (TME) due to immunosuppressive signals scarcity nutrients. NK cells central anti-tumor immunity can directly eliminate without prior...
CD19-targeted immunotherapies that stimulate a cytotoxic T-cell response have revolutionized the management of B-cell malignancies, specifically relapsed or refractory acute lymphoblastic leukemia (R/ R ALL).Blinatumomab is an anti-CD19 bispecific engager approved for treatment patients with R/R ALL. 1 KTE-X19 autologous chimeric antigen receptor (CAR) therapy under investigation in ZUMA-3 (XXX) phase 1/2 clinical trial (registered at www.clinicaltrials.gov2][3][4][5] Several distinct...
Abstract CD47 is a cell surface glycoprotein that interacts with signal regulatory protein alpha (SIRPα) on macrophages and dendritic cells triggering “don't eat me” inhibits phagocytosis. Many tumors evade immune surveillance by overexpressing CD47, thereby preventing their recognition phagocytes. Blocking the interaction of SIRPα/CD47 promotes phagocytosis tumor destruction leading to reduction in burden. We have developed humanized anti-CD47 antibody, AO-176, blocks between SIRPα exhibits...
Abstract Recent success in cancer immunotherapy has targeted immune checkpoints such as PD-1, PDL-1, and CTLA-4 to enhance the cytotoxic activity of adaptive T-cell response. While clinical response these therapies been dramatic for some, many others have shown partial or even no highlighting need alternative synergistic approaches that activate innate immunity. Disruption interaction between SIRP alpha CD47, an checkpoint inhibitor, using anti-CD47 antibodies, example, is known immunity by...
Abstract We have used Arrayed Imaging Reflectometry (AIR™), a label-free protein microarray technology that relies on the target binding-induced perturbation of an antireflective coating surface silicon biosensor, to create multiplex antibody array for detection human and murine serum cytokines inflammatory markers. The biosensor is capable providing quantitative concentrations, with limits in low picograms per mL. Provided standard 96-well microplate format, nature enables flexible creation...